GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV ...

GSK Plc's U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and launched a $2.5 billion stock buyback on the back of optimism about sales of its new drugs ...

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The company’s shares closed last Friday at p1,405. ...

European markets opened mixed on Wednesday, with investors looking ahead to more earnings from a number of key companies.

UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of p1,580.00. The company’s shares opened today at p1,392.50. According ...

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...

GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has ...

GSK's business development team have been working overtime of late, with three R&D deals announced in the last few days across Alzheimer's disease and cancer. The Alzheimer's agreement – with ...

Teva Pharmaceutical Industries Ltd. ADR-0.62% $20.28B ...

As of January 30 at 3:40:30 PM EST. Market Open.

As of January 29 at 9:30:09 AM EST. Market Open.

As of 31 January at 11:44:11 am GMT-5. Market Open.